197 related articles for article (PubMed ID: 34529911)
1. Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
Knez J; Sobocan M; Belak U; Kavalar R; Zupin M; Büdefeld T; Potocnik U; Takac I
Radiol Oncol; 2021 Sep; 56(1):76-82. PubMed ID: 34529911
[TBL] [Abstract][Full Text] [Related]
2. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
[TBL] [Abstract][Full Text] [Related]
3. Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice.
de Biase D; Maloberti T; Corradini AG; Rosini F; Grillini M; Ruscelli M; Coluccelli S; Altimari A; Gruppioni E; Sanza V; Turchetti D; Galuppi A; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; De Leo A
Front Med (Lausanne); 2023; 10():1146499. PubMed ID: 37064027
[TBL] [Abstract][Full Text] [Related]
4. A novel algorithm to implement the molecular classification according to the new ESGO/ESTRO/ESP 2020 guidelines for endometrial cancer.
Betella I; Fumagalli C; Rafaniello Raviele P; Schivardi G; De Vitis LA; Achilarre MT; Aloisi A; Garbi A; Maruccio M; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Colombo N; Multinu F
Int J Gynecol Cancer; 2022 Jun; ():. PubMed ID: 35732351
[TBL] [Abstract][Full Text] [Related]
5. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
6. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
7. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
[TBL] [Abstract][Full Text] [Related]
8. Identification of
Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of lymphovascular space invasion according to the molecular subgroups in endometrial cancer.
Siegenthaler F; Epstein E; Büchi CA; Gmür A; Saner FACM; Rau TT; Carlson JW; Mueller MD; Imboden S
Int J Gynecol Cancer; 2023 Nov; 33(11):1702-1707. PubMed ID: 37666529
[TBL] [Abstract][Full Text] [Related]
10. PErsonalized TReatment for Endometrial Carcinoma (PETREC): study design and methods of a prospective Finnish multicenter trial.
Loukovaara M; Bützow R; Staff S; Mäenpää M; Faltinová M; Lassus H; Veijalainen O; Grönvall M; Vaalavirta L; Kuikka E; Haataja M; Urpilainen E; Simojoki M; Anttila M; Auranen A
Int J Gynecol Cancer; 2023 Nov; 33(11):1807-1811. PubMed ID: 37813479
[TBL] [Abstract][Full Text] [Related]
11. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
[TBL] [Abstract][Full Text] [Related]
13. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
14. Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features.
Kang EY; Wiebe NJ; Aubrey C; Lee CH; Anglesio MS; Tilley D; Ghatage P; Nelson GS; Lee S; Köbel M
J Pathol Clin Res; 2022 Jan; 8(1):19-32. PubMed ID: 34596362
[TBL] [Abstract][Full Text] [Related]
15. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
16. Endometrial Cancer: Transitioning from Histology to Genomics.
Mitric C; Bernardini MQ
Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification of endometrial carcinoma, is it the new era of precision medicine?
Bidzinski M; Danska-Bidzinska A; Rychlik A; Kypryjanczyk J; Pyzlak M; Piatek S
Ginekol Pol; 2022; 93(2):163-167. PubMed ID: 35072255
[TBL] [Abstract][Full Text] [Related]
18. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
RAINBO Research Consortium
Int J Gynecol Cancer; 2022 Dec; 33(1):109-17. PubMed ID: 36600534
[TBL] [Abstract][Full Text] [Related]
19. Impact of the new molecular classification of endometrial cancer: A French cohort study.
Benichou J; Schwall C; Sastre-Garau X; Méreaux J; Miailhe G; Bendifallah S; Haddad B; Touboul C; Mitri-Frangieh R; Dabi Y
Gynecol Oncol; 2022 Sep; 166(3):515-521. PubMed ID: 35843738
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review.
De Vitis LA; Schivardi G; Caruso G; Fumagalli C; Vacirca D; Achilarre MT; Aloisi A; Garbi A; Zanagnolo V; Aletti G; Guerini-Rocco E; Mariani A; Maggioni A; Barberis M; Bogani G; Colombo N; Multinu F; Betella I
Int J Gynecol Cancer; 2023 Dec; ():. PubMed ID: 38135437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
